Derivatives of prostate-specific antigen as predictors of incidental prostate cancer

BJU International

Volumn 104, Issue 1, 2009, Pages 25-28

  Froehner, Michael ^a   Buck, Lena Marie ^a   Koch, Rainer ^a   Hakenberg, Oliver W ^b   Wirth, Manfred P ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Derivatives; Incidental prostate cancer; Prostate biopsy; Prostate specific antigen; Transurethral resection

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; HUMAN; INCIDENTAL FINDING; INDWELLING CATHETER; MAJOR CLINICAL STUDY; MALE; PATIENT IDENTIFICATION; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY; TRANSURETHRAL RESECTION;

AGED; EPIDEMIOLOGIC METHODS; HUMANS; INCIDENTAL FINDINGS; MALE; MIDDLE AGED; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TRANSURETHRAL RESECTION OF PROSTATE;

EID: 67650488956     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.08349.x     Document Type: Article

References (16)

1. Van Renterghem K, Van Koeveringe G, Achten R, Van Kerrebroeck P. Clinical relevance of transurethral resection of the prostate in 'asymptomatic' patients with an elevated prostate-specific antigen level. Eur Urol 2007 52 : 819 26
2. Thompson I, Thrasher JB, Aus G et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2007 177 : 2106 31
3. American Urological Association. Guideline on the management of benign prostatic hyperplasia (BPH) 2006 update. Available at: http://www.auanet.org/ content/guidelines-and-quality-care/clinical-guidelines.cfm?sub=bph. Accessed November 2008
4. Heidenreich A, Aus G, Bolla M et al. EAU guidelines on prostate cancer. Eur Urol 2008 53 : 68 80 (Pubitemid 350166735)
5. De la Rosette J, Alivizatos G, Madersbacher S et al. Guidelines on Benign Prostatic Hyperplasia 2006 Update. Available at: http://www.uroweb.org/ fileadmin/user-upload/Guidelines/11%20BPH.pdf. Accessed December 2008
6. DeLong R, DeLong D, Clarke-Pearson D. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988 44 : 837 45
7. Roddam AW, Duffy MJ, Hamdy FC et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol 2005 48 : 386 99
8. Fowler JE, Bigler SA, Kolski JM. Prostate cancer detection in candidates for open prostatectomy. J Urol 1998 160 : 2107 10
9. Ornstein DK, Rao GS, Smith DS, Andriole GL. The impact of systematic prostate biopsy on prostate cancer incidence in men with symptomatic benign prostatic hyperplasia undergoing transurethral resection of the prostate. J Urol 1997 157 : 880 4
10. Batislam E, Arik AI, Karakoc A, Uygur MC, Germiyanolu RC, Erol D. Effect of transurethral indwelling catheter on serum prostate-specific antigen level in benign prostatic hyperplasia. Urology 1997 49 : 50 4
11. Okegawa T, Noda H, Nutahara K, Higashihara E. Comparisons of the various combinations of free, complexed, and total prostate-specific antigen for the detection of prostate cancer. Eur Urol 2000 38 : 380 7
12. Djavan B, Remzi M, Zlotta AR et al. Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial. Urology 2002 60 (Suppl. 1 4 9
13. Ozdal OL, Aprikian AG, Bégin LR, Behlouli H, Tanguay S. Comparative evaluation of various prostate specific antigen ratios for the early detection of prostate cancer. BJU Int 2004 93 : 970 4
14. Tombal B, De Visccher L, Cosyns JP et al. Assessing the risk of unsuspected prostate cancer in patients with benign prostatic hypertrophy: a 13-year retrospective study of the incidence and natural history of T1a-T1b prostate cancers. BJU Int 1999 84 : 1015 20
15. Merrill RM, Wiggins CL. Incidental detection of population-based prostate cancer incidence rates through transurethral resection of the prostate. Urol Oncol 2002 7 : 213 9
16. Thompson IM, Pauler DK, Goodman PJ et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004 350 : 2239 46